Representing and Reasoning with Temporal Constraints in Clinical Trials Using Semantic Technologies

2008 ◽  
pp. 520-530
Author(s):  
Ravi D. Shankar ◽  
Susana B. Martins ◽  
Martin J. O’Connor ◽  
David B. Parrish ◽  
Amar K. Das
Keyword(s):  
Clinical Trials ◽  
Temporal Constraints ◽  
Semantic Technologies

Stepwise Semantic Enrichment in Health-Related Public Management by Using Semantic Information Models

2011 ◽  
pp. 195-212 ◽  
Author(s):  
Hans-Georg Fill ◽  
Ilona Reischl
Keyword(s):  
Clinical Trials ◽  
Public Management ◽  
Conceptual Models ◽  
Competent Authority ◽  
Semantic Technologies ◽  
Semantic Enrichment ◽  
Information Models ◽  
Healthcare It ◽  
Health Related ◽  
Meta Modeling

The use of semantic technologies in practical scenarios requires carefully balancing the tradeoff between costs and benefits in order to gain acceptance. In this chapter we report on a project conducted together with the Austrian competent authority in regard to safety in healthcare. It is described how semantic technologies can be combined with conceptual models to support management executives in the distribution of knowledge and the analysis of compliance. The approach is based on a step-wise semantic enrichment of conceptual models with formal semantic schemata in order to support human analyses. It has been implemented on the ADONIS meta modeling platform and applied to a scenario dealing with the management of applications for clinical trials.

Localization of Gallium-67 in Peritoneal Cells by Electron Microscopic Autoradiography

1973 ◽  
Vol 31 ◽  
pp. 404-405
Author(s):  
D. C. Swartzendruber ◽  
Norma L. Idoyaga-Vargas
Keyword(s):  
Clinical Trials ◽  
Soft Tissue ◽  
Tumor Tissue ◽  
Soft Tissue Tumors ◽  
Clinical Usefulness ◽  
Electron Microscopic ◽  
Normal Cells ◽  
Electron Microscopic Autoradiography ◽  
Peritoneal Cells ◽  
Gallium 67

The radionuclide gallium-67 (67Ga) localizes preferentially but not specifically in many human and experimental soft-tissue tumors. Because of this localization, 67Ga is used in clinical trials to detect humar. cancers by external scintiscanning methods. However, the fact that 67Ga does not localize specifically in tumors requires for its eventual clinical usefulness a fuller understanding of the mechanisms that control its deposition in both malignant and normal cells. We have previously reported that 67Ga localizes in lysosomal-like bodies, notably, although not exclusively, in macrophages of the spocytaneous AKR thymoma. Further studies on the uptake of 67Ga by macrophages are needed to determine whether there are factors related to malignancy that might alter the localization of 67Ga in these cells and thus provide clues to discovering the mechanism of 67Ga localization in tumor tissue.

Patients' satisfaction in clinical trials

2000 ◽  
Vol 248 (6) ◽  
pp. 441-442 ◽  
Author(s):  
L. Terenius
Keyword(s):  
Clinical Trials ◽  
Patients Satisfaction

Rome I versus Rome II; Overlap in patients enrolled in tegaserod phase III clinical trials for irritable bowel syndrome (IBS)

2001 ◽  
Vol 120 (5) ◽  
pp. A284-A284
Author(s):  
B NAULT ◽  
S SUE ◽  
J HEGGLAND ◽  
S GOHARI ◽  
G LIGOZIO ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Irritable Bowel Syndrome ◽  
Phase Iii ◽  
Phase Iii Clinical Trials ◽  
Irritable Bowel ◽  
Rome I

Clinical trials screening: An opportunity to increase medical care access

2001 ◽  
Vol 120 (5) ◽  
pp. A410-A410
Author(s):  
T KOVASC ◽  
R ALTMAN ◽  
R JUTABHA ◽  
G OHNING
Keyword(s):  
Clinical Trials ◽  
Medical Care ◽  
Care Access

The Payoffs and Pitfalls of Participating in Clinical Trials

2008 ◽  
Vol 39 (4) ◽  
pp. 53
Author(s):  
CAROLYN SACHS
Keyword(s):  
Clinical Trials
Sign in / Sign up

Export Citation Format

Share Document